4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press
Abstract
Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8]. © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
Description
Keywords
Abc, Advanced, Breast cancer, Eso-esmo, Guidelines, Metastatic, Biomarkers, tumor, Biopsy, large-core needle, Breast, Breast neoplasms, Chemoradiotherapy, adjuvant, Clinical trials as topic, Consensus development conferences as topic, Europe, Evidence-based medicine, Female, Humans, Integrative medicine, Mastectomy, Medical oncology, Neoadjuvant therapy, Neoplasm staging, Societies, medical, Treatment outcome, Abemaciclib, Anthracycline derivative, Antineoplastic metal complex, Benzodiazepine derivative, Bevacizumab, Biological response modifier, Bisphosphonic acid derivative, Bleomycin, Capecitabine, Cyclophosphamide, Denosumab, Eribulin, Everolimus, Fulvestrant, Gemcitabine, Lapatinib, Methotrexate, Olaparib, Opiate, Palbociclib, Pertuzumab, Steroid, Talazoparib, Tamoxifen, Taxane derivative, Trastuzumab, Tricyclic antidepressant agent, Unindexed drug, Vinorelbine tartrate, Zoledronic acid, Tumor marker, Anxiety disorder, Article, Bone metastasis, Brain metastasis, Brain surgery, Cancer fatigue, Cancer immunotherapy, Cancer palliative therapy, Cancer radiotherapy, Cancer recurrence, Cancer staging, Cancer surgery, Chemotherapy induced nausea and vomiting, Chemotherapy-induced peripheral neuropathy, Consensus, Diarrhea, Drug efficacy, Dyspnea, Estrogen receptor positive breast cancer, Hereditary tumor syndrome, Human, Human epidermal growth factor receptor 2 positive breast cancer, Liver metastasis, Liver toxicity, Male breast cancer, Malignant pleura effusion, Morbidity, Neutropenia, Personalized medicine, Practice guideline, Priority journal, Progression free survival, Radiosurgery, Support group, Triple negative breast cancer, Tumor biopsy, Tumor localization, Adjuvant chemoradiotherapy, Breast tumor, Clinical trial (topic), Consensus development, Diagnostic imaging, Evidence based medicine, Genetics, Large core needle biopsy, Medical society, Metabolism, Oncology, Pathology, Procedures, Surgery